参考文献/References:
[1]McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Rev Esp Cardiol (Engl Ed),2022,75(6):523.
[2]Groenewegen A,Rutten FH,Mosterd A,et al. Epidemiology of heart failure[J]. Eur J Heart Fail,2020,22(8):1342-1356.
[3]Pierce JB,Li Z,Greiner MA,et al. Adoption of sacubitril/valsartan among patients with heart failure with mildly reduced or preserved ejection fraction:the get with the guidelines—Heart failure registry[J]. Circ Heart Fail,2023,16(1):e010176.
[4]Emdin M,Aimo A,Castiglione V,et al. Targeting cyclic guanosine monophosphate to treat heart failure:JACC review topic of the week[J]. J Am Coll Cardiol,2020,76(15):1795-1807.
[5]Boettcher M,Gerisch M,Lobmeyer M,et al. Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat,a soluble guanylate cyclase stimulator:results from preclinical and phase i healthy volunteer studies[J]. Clin Pharmacokinet,2020,59(11):1407-1418.
[6]Aimo A,Castiglione V,Vergaro G,et al. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction[J]. Heart Fail Rev,2022,27(4):1165-1171.
[7]Varela-Chinchilla CD,Sánchez-Mejía DE,Trinidad-Calderón PA. Congenital heart disease:the state-of-the-art on its pharmacological therapeutics[J]. J Cardiovasc Dev Dis,2022,9(7):201.
[8]Sandner P. From molecules to patients:exploring the therapeutic role of soluble guanylate cyclase stimulators[J]. Biol Chem,2018,399(7):679-690.
[9]Follmann M,Ackerstaff J,Redlich G,et al. Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure[J]. J Med Chem,2017,60(12):5146-5161.
[10]Zern EK,Ho JE,Panah LG,et al. Exercise intolerance in heart failure with preserved ejection fraction:arterial stiffness and aabnormal left ventricular hemodynamic responses during exercise[J]. J Card Fail,2021,27(6):625-634.
[11]Kemp-Harper BK,Velagic A,Paolocci N,et al. Cardiovascular therapeutic potential of the redox siblings,nitric oxide (NO*) and nitroxyl (HNO),in the setting of reactive oxygen species dysregulation[J]. Handb Exp Pharmacol,2021,264:311-337.
[12]Hulot JS,Trochu JN,Donal E,et al. Vericiguat for the treatment of heart failure:mechanism of action and pharmacological properties compared with other emerging therapeutic options[J]. Expert Opin Pharmacother,2021,22(14):1847-1855.
[13]Cai Y,Zhang B,Shalamu A,et al. Soluble guanylate cyclase (sGC) stimulator vericiguat alleviates myocardial ischemia-reperfusion injury by improving microcirculation[J]. Ann Transl Med,2022,10(12):662.
[14]Masuyama H,Tsuruda T,Sekita Y,et al. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart[J]. Hypertens Res,2009,32(7):597-603.
[15]Rosa I,Fioretto BS,Romano E,et al. The soluble guanylate cyclase stimulator BAY 41-2272 attenuates transforming growth factor beta1-induced myofibroblast differentiation of human corneal keratocytes[J]. Int J Mol Sci,2022,23(23):15325.
[16]Naesheim T,How OJ,Myrmel T. The effect of Riociguat on cardiovascular function and efficiency in healthy,juvenile pigs[J]. Physiol Rep,2020,8(17):e14562.
[17]Desbiens LC,Goulamhoussen N,Fortier C,et al. Enhancing central blood pressure accuracy through statistical modeling:a proof-of-concept study[J]. Front Cardiovasc Med,2022,9:1048507.
[18]Boden K,Sandner P,Roessig L,et al. Vericiguat improves aortic wave reflection parameters in a new preclinical model of hypertension[J]. Circ Heart Fail,2022,15(1):e008735.
[19]Fu H,Zhang J,Cai Q,et al. Pleiotropic roles of atrial natriuretic peptide in anti-inflammation and anti-cancer activity[J]. Cancers (Basel),2022,14(16):3981.
[20]Ahluwalia A,Foster P,Scotland RS,et al. Antiinflammatory activity of soluble guanylate cyclase:cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment[J]. Proc Natl Acad Sci U S A,2004,101(5):1386-1391.
[21]Ataei Ataabadi E,Golshiri K,Jüttner AA,et al. Soluble guanylate cyclase activator BAY 54-6544 improves vasomotor function and survival in an accelerated ageing mouse model[J]. Aging Cell,2022,21(9):e13683.
[22]Kramer F,Voss S,Roessig L,et al. Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction[J]. Eur J Heart Fail,2020,22(9):1675-1683.
[23]Suthahar N,Lau ES,Blaha MJ,et al. Sex-specific associations of cardiovascular risk factors and biomarkers with incident heart failure[J]. J Am Coll Cardiol,2020,76(12):1455-1465.
[24]Saito Y,Tanaka A,Node K,et al. Uric acid and cardiovascular disease:a clinical review[J]. J Cardiol,2021,78(1):51-57.
[25]Boettcher M,Thomas D,Mueck W,et al. Safety,pharmacodynamic,and pharmacokinetic characterization of vericiguat:results from six phase Ⅰ studies in healthy subjects[J]. Eur J Clin Pharmacol,2021,77(4):527-537.
[26]Boettcher M,Loewen S,Gerrits M,et al. Pharmacodynamic and pharmacokinetic interaction profile of vericiguat:results from three randomized phase Ⅰ studies in healthy volunteers[J]. Clin Pharmacokinet,2021,60(3):337-351.
[27]Gheorghiade M,Greene S J,Butler J,et al. Effect of vericiguat,a soluble guanylate cyclase stimulator,on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction:the SOCRATES-REDUCED randomized trial[J]. JAMA,2015,314(21):2251-2262.
[28]Armstrong PW,Roessig L,Patel MJ,et al. A multicenter,randomized,double-blind,placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator:the VICTORIA trial[J]. JACC Heart Fail,2018,6(2):96-104.
[29]Pieske B,Patel MJ,Westerhout CM,et al. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial[J]. Eur J Heart Fail,2019,21(12):1596-1604.
[30]Pieske B,Maggioni AP,Lam CSP,et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction:results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study[J]. Eur Heart J,2017,38(15):1119-1127.
[31]Armstrong PW,Lam CSP,Anstrom KJ,et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction:the VITALITY-HFpEF randomized clinical trial[J]. JAMA,2020,324(15):1512-1521.
[32]Bedawi EO,Ricciardi S,Hassan M,et al. ERS/ESTS statement on the management of pleural infection in adults[J]. Eur Respir J,2023,61(2):2201062.
[33]Sarmah N,Nauli AM,Ally A,et al. Interactions among endothelial nitric oxide synthase,cardiovascular system,and nociception during physiological and pathophysiological states[J]. Molecules,2022,27(9):2835.
[34]Liu T,Schroeder H,Power GG,et al. A physiologically relevant role for NO stored in vascular smooth muscle cells:a novel theory of vascular NO signaling[J]. Redox Biol,2022,53:102327.
[35]Rainer PP,Kass DA. Old dog,new tricks:novel cardiac targets and stress regulation by protein kinase G[J]. Cardiovasc Res,2016,111(2):154-162.
[36]Karna KK,Choi BR,Kim CY,et al. Rubus occidentalis and ellagic acid affect the contractility of penile corpus cavernosum smooth muscle through the nitric oxide-cyclic guanosine monophosphate and cyclic adenosine 3’,5’-monophosphate signaling pathway[J]. J Clin Med,2022,11(10):2947.
[37]Kang C,Lamb YN. Vericiguat:a review in chronic heart failure with reduced ejection fraction[J]. Am J Cardiovasc Drugs,2022,22(4):451-459.
[38]González-Juanatey JR,Anguita-Sánchez M,Bayes-Genís A,et al. Vericiguat in heart failure:from scientific evidence to clinical practice[J]. Rev Clin Esp (Barc),2022,222(6):359-369.
[39]Vannuccini F,Campora A,Barilli M,et al. Vericiguat in heart failure:characteristics,scientific evidence and potential clinical applications[J]. Biomedicines,2022,10(10):2471.
[40]McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.
相似文献/References:
[1]戴玫,付珞,胡建英,等.慢性心力衰竭患者应用高强度间歇性有氧训练研究进展[J].心血管病学进展,2016,(3):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
DAI Mei,FU Luo,HU Jianying,et al.Advances in Research on High-intensity Interval Training in Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2016,(8):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
[2]张培,综述,刘剑,等.慢性心力衰竭并发肌少症的研究进展[J].心血管病学进展,2016,(3):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
ZHANG Pei,LIU Jian.Research Progress in Chronic Heart Failure-induced Sarcopenia[J].Advances in Cardiovascular Diseases,2016,(8):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
[3]田晶,张青,张岩波,等.慢性心力衰竭结局评价指标研究进展[J].心血管病学进展,2019,(6):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
TIAN Jing,ZHANG qing,ZHANG Yanbo,et al.Outcome Indicators for Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
[4]胡威,苏芳菊,张卫泽.左室四极导线在心脏再同步化治疗中的应用进展[J].心血管病学进展,2020,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
HU Wei,SU Fangju,ZHANG Weize.Application of Left Ventricular Quadrupole in Cardiac Resynchronization Therapy[J].Advances in Cardiovascular Diseases,2020,(8):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
[5]郭岐龙 芦颜美 张玲 张疆华 邢强 祖克拉·吐尔洪 李耀东 周贤惠 汤宝鹏.新疆地区老年慢性心力衰竭住院患者的病因、合并症及药物治疗的多中心回顾性分析[J].心血管病学进展,2020,(4):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
GUO Qilong,LU Yanmei,ZHANG Ling,et al.Etiology, Comorbidity and Drug Treatment of Elderly Inpatients with Chronic Heart Failure in Xinjiang: A Multi-center Retrospective Study[J].Advances in Cardiovascular Diseases,2020,(8):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
[6]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(8):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[7]郭曦滢,孙煌,樊朝美,等.非奈利酮治疗慢性心力衰竭的研究进展[J].心血管病学进展,2020,(10):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
GUO XiyingSUN HuangFAN ChaomeiZHANG Jian.Finerenone in the Treatment of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(8):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
[8]吴燕婷 李萍 吴寒.慢性心力衰竭再住院率研究进展[J].心血管病学进展,2021,(8):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
WU Yanting,LI Ping,WU Han.Rehospitalization Rate of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2021,(8):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
[9]高源 郑刚 李嫣红 张鼎.维利西呱治疗心力衰竭新进展[J].心血管病学进展,2021,(8):698.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.007]
Gao Yuan Zheng Gang Li Yan Hong Zhang Ding.Treatment of Heart Failure with Vericiguat[J].Advances in Cardiovascular Diseases,2021,(8):698.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.007]
[10]陈晓梅 陈巧玮 曾纪娟 张庆.可穿戴设备在慢性心力衰竭患者管理中的应用进展[J].心血管病学进展,2023,(3):233.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.010]
CHEN Xiaomei,CHEN Qiaowei,ZENG Jijuan,et al.Application of Wearable Devices in Management of Patients with Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2023,(8):233.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.010]